Medtronic (2M6) Stock Forecast & Price Target

9 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2M6 Analyst Ratings

Moderate Buy

12 Buy

8 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Medtronic

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2M6 Stock 12 Month Forecast

Average Price Target

€92.07

▲(17.23% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is €92.07 with a high forecast of €105.06 and a low forecast of €75.68. The average price target represents a 17.23% change from the last price of €78.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"62":"€62","73":"€73","84":"€84","95":"€95","106":"€106"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105.06362106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€105.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.0746988152941,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€92.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.68142195,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€75.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[62,73,84,95,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.44,78.64181700461538,80.84363400923077,83.04545101384615,85.24726801846154,87.44908502307692,89.65090202769231,91.85271903230769,94.05453603692308,96.25635304153846,98.45817004615385,100.65998705076923,102.86180405538462,{"y":105.06362106,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.44,77.642669139638,78.845338279276,80.04800741891403,81.25067655855203,82.45334569819003,83.65601483782804,84.85868397746606,86.06135311710406,87.26402225674207,88.46669139638007,89.66936053601809,90.8720296756561,{"y":92.0746988152941,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.44,76.38164784230769,76.32329568461539,76.26494352692308,76.20659136923076,76.14823921153847,76.08988705384616,76.03153489615384,75.97318273846153,75.91483058076923,75.85647842307692,75.79812626538461,75.73977410769231,{"y":75.68142195,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.311,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.291,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.659,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.213,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.864,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.744,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.176,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.199,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.09,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.886,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.932,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.903,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.44,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€105.06

Average Price Target€92.07

Lowest Price Target€75.68

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

€97.94

Buy

24.70%

Upside

Reiterated

10/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (NYSE: MDT) and Regeneron (NASDAQ: REGN)

Kendall Au

RBC Capital

€105.06

Buy

33.77%

Upside

Reiterated

10/01/26

RBC Capital Keeps Their Buy Rating on Medtronic (MDT)

Josh Jennings

TD Cowen

€97.94

Buy

24.70%

Upside

Reiterated

09/30/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Conavi Medical (Other OTC: CNVIF)

Matthew O'Brien

Piper Sandler

€75.68

Hold

-3.64%

Downside

Reiterated

09/28/26

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Medtronic (NYSE: MDT)

Michael Matson

Needham

€101.5

Buy

29.24%

Upside

Reiterated

09/17/26

Medtronic Reaffirmed at Buy as $700M Cornerstone Robotics Deal Strengthens Surgical Portfolio; Price Target Unchanged at $114

Travis Steed

Bank of America Securities

€97.94

Buy

24.70%

Upside

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Adagene (NASDAQ: ADAG) and Medtronic (NYSE: MDT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/10/26

Analyst Brandon Vazquez Reaffirms Buy on Medtronic, Citing Strong FY2027 Outlook and Attractive Risk‑Reward Profile

Larry Biegelsen

Wells Fargo

€92.6

Buy

17.90%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Pito Chickering

Deutsche Bank

€69.45→€81.91

Hold

4.30%

Upside

Assigned

09/03/26

Medtronic price target raised to $92 from $78 at Deutsche BankMedtronic price target raised to $92 from $78 at Deutsche Bank

Robbie Marcus

J.P. Morgan

€76.57→€85.48

Hold

8.83%

Upside

Reiterated

09/03/26

J.P. Morgan Keeps Their Hold Rating on Medtronic (MDT)

Patrick Wood

UBS

€89.04→€97.94

Buy

24.70%

Upside

Assigned

09/03/26

Medtronic price target raised to $110 from $100 at UBSMedtronic price target raised to $110 from $100 at UBS

Jayson Bedford

Raymond James

―

Hold

―

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE), Medtronic (NYSE: MDT) and Immunic (NASDAQ: IMUX)

Anthony Petrone

Mizuho Securities

€89.04→€102.39

Buy

30.37%

Upside

Reiterated

09/02/26

Medtronic price target raised to $115 from $100 at MizuhoMedtronic price target raised to $115 from $100 at Mizuho

Matthew Taylor

Jefferies

€84.59

Hold

7.70%

Upside

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Medtronic (NYSE: MDT)

Richard Newitter

Truist Financial

€76.57→€88.15

Hold

12.23%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Medtronic (NYSE: MDT) and AbCellera Biologics (NASDAQ: ABCL)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

€97.94

Buy

24.70%

Upside

Reiterated

10/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (NYSE: MDT) and Regeneron (NASDAQ: REGN)

Kendall Au

RBC Capital

€105.06

Buy

33.77%

Upside

Reiterated

10/01/26

RBC Capital Keeps Their Buy Rating on Medtronic (MDT)

Josh Jennings

TD Cowen

€97.94

Buy

24.70%

Upside

Reiterated

09/30/26

Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Conavi Medical (Other OTC: CNVIF)

Matthew O'Brien

Piper Sandler

€75.68

Hold

-3.64%

Downside

Reiterated

09/28/26

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and Medtronic (NYSE: MDT)

Michael Matson

Needham

€101.5

Buy

29.24%

Upside

Reiterated

09/17/26

Medtronic Reaffirmed at Buy as $700M Cornerstone Robotics Deal Strengthens Surgical Portfolio; Price Target Unchanged at $114

Travis Steed

Bank of America Securities

€97.94

Buy

24.70%

Upside

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Adagene (NASDAQ: ADAG) and Medtronic (NYSE: MDT)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

09/10/26

Analyst Brandon Vazquez Reaffirms Buy on Medtronic, Citing Strong FY2027 Outlook and Attractive Risk‑Reward Profile

Larry Biegelsen

Wells Fargo

€92.6

Buy

17.90%

Upside

Reiterated

09/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Pito Chickering

Deutsche Bank

€69.45→€81.91

Hold

4.30%

Upside

Assigned

09/03/26

Medtronic price target raised to $92 from $78 at Deutsche BankMedtronic price target raised to $92 from $78 at Deutsche Bank

Robbie Marcus

J.P. Morgan

€76.57→€85.48

Hold

8.83%

Upside

Reiterated

09/03/26

J.P. Morgan Keeps Their Hold Rating on Medtronic (MDT)

Patrick Wood

UBS

€89.04→€97.94

Buy

24.70%

Upside

Assigned

09/03/26

Medtronic price target raised to $110 from $100 at UBSMedtronic price target raised to $110 from $100 at UBS

Jayson Bedford

Raymond James

―

Hold

―

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE), Medtronic (NYSE: MDT) and Immunic (NASDAQ: IMUX)

Anthony Petrone

Mizuho Securities

€89.04→€102.39

Buy

30.37%

Upside

Reiterated

09/02/26

Medtronic price target raised to $115 from $100 at MizuhoMedtronic price target raised to $115 from $100 at Mizuho

Matthew Taylor

Jefferies

€84.59

Hold

7.70%

Upside

Reiterated

09/02/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (NASDAQ: UTHR) and Medtronic (NYSE: MDT)

Richard Newitter

Truist Financial

€76.57→€88.15

Hold

12.23%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Medtronic (NYSE: MDT) and AbCellera Biologics (NASDAQ: ABCL)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

KURAKura Oncology

DNLIDenali Therapeutics

OVIDOvid Therapeutics

HITIHigh Tide

AXGNAxoGen

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

3 Months

Patrick WoodUBS

Success Rate

11/15 ratings generated profit

Average Return

+2.73%

Copying Patrick Wood's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +2.73% per trade.

1 Year

Patrick WoodUBS

Success Rate

12/15 ratings generated profit

Average Return

+6.05%

Copying Patrick Wood's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +6.05% per trade.

2 Years

Vijay KumarEvercore ISI

Success Rate

16/20 ratings generated profit

Average Return

+8.33%

Copying Vijay Kumar's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +8.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2M6 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2M6 has received 26 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 2M6 average Analyst price target in the past 3 months is 92.07.

Each month's total comprises the sum of three months' worth of ratings.

2M6 Financial Forecast

2M6 Earnings Forecast

Next quarter’s earnings estimate for 2M6 is €1.19 with a range of €1.18 to €1.24. The previous quarter’s EPS was €1.29. 2M6 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2M6 has Performed in-line its overall industry.

2M6 Sales Forecast

Next quarter’s sales forecast for 2M6 is €8.44B with a range of €8.41B to €8.49B. The previous quarter’s sales results were €8.69B. 2M6 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2M6 has Performed in-line its overall industry.

2M6 Stock Forecast FAQ

What is DE:2M6’s average 12-month price target, according to analysts?

Based on analyst ratings, Medtronic’s 12-month average price target is 92.07.

What is DE:2M6’s upside potential, based on the analysts’ average price target?

Medtronic has 17.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Medtronic a Buy, Sell or Hold?

Medtronic has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 8 hold ratings and 0 sell ratings.

What is Medtronic’s share price target?

The average share price target for Medtronic is 92.07. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €105.06 ,and the lowest forecast is €75.68. The average share price target represents 17.23% Increase from the current price of €78.54.

What do analysts say about Medtronic?

Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Medtronic?

To buy shares of DE:2M6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Medtronic (2M6) Stock Forecast & Price Target

2M6 Analyst Ratings

2M6 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medtronic

2M6 Analyst Recommendation Trends

2M6 Financial Forecast

2M6 Earnings Forecast

2M6 Sales Forecast

2M6 Stock Forecast FAQ

Detailed List of Analyst Forecasts